BROOMFIELD, Colo.--(BUSINESS WIRE)--Animal studies of a potentially breakthrough medical technology that uses a novel antisense agent to arrest the process of coronary arteries becoming reblocked after treatment with angioplasty and stenting have shown highly promising results, a spokesman for Global Therapeutics, a Cook Medical company, announced today. Global Therapeutics reports that preclinical studies have shown successful delivery of the agent to the specific site of stenting. Delivery of a therapeutic dose of the antisense agent was achieved safely without any adverse systemic effects. Furthermore, it was shown that the target RNA, from the c-myc gene, one of the main causes of restenosis, was effectively inhibited by the antisense compound AVI-5126 developed by Cook Medical’s partner AVI BioPharma, Inc. (Nasdaq: AVII).
